TNSN07474A1 - Dosage regimen for prasugrel - Google Patents

Dosage regimen for prasugrel

Info

Publication number
TNSN07474A1
TNSN07474A1 TNP2007000474A TNSN07474A TNSN07474A1 TN SN07474 A1 TNSN07474 A1 TN SN07474A1 TN P2007000474 A TNP2007000474 A TN P2007000474A TN SN07474 A TNSN07474 A TN SN07474A TN SN07474 A1 TNSN07474 A1 TN SN07474A1
Authority
TN
Tunisia
Prior art keywords
prasugrel
dosage regimen
pharmaceutically acceptable
acceptable salt
loading
Prior art date
Application number
TNP2007000474A
Other languages
English (en)
Inventor
John Thomas Brandt
Nagy Alphonse Farid
Joseph Anthony Jakubowski
Christopher David Payne
Govinda Jayanath Weerakkody
Kenneth John Winters
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TNSN07474A1 publication Critical patent/TNSN07474A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TNP2007000474A 2005-06-17 2007-12-14 Dosage regimen for prasugrel TNSN07474A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17
PCT/US2006/023006 WO2006138317A2 (en) 2005-06-17 2006-06-13 Dosage regimen for prasugrel

Publications (1)

Publication Number Publication Date
TNSN07474A1 true TNSN07474A1 (en) 2009-03-17

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000474A TNSN07474A1 (en) 2005-06-17 2007-12-14 Dosage regimen for prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (enExample)
EP (1) EP1893205A4 (enExample)
JP (1) JP2008543853A (enExample)
KR (1) KR20080016647A (enExample)
CN (1) CN101198329A (enExample)
AU (1) AU2006259538A1 (enExample)
BR (1) BRPI0612624A2 (enExample)
CA (1) CA2612315A1 (enExample)
EA (1) EA200800075A1 (enExample)
EC (1) ECSP078014A (enExample)
GT (1) GT200600263A (enExample)
IL (1) IL187486A0 (enExample)
MA (1) MA29722B1 (enExample)
MX (1) MX2007015430A (enExample)
NO (1) NO20080244L (enExample)
TN (1) TNSN07474A1 (enExample)
WO (1) WO2006138317A2 (enExample)
ZA (1) ZA200710769B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672154C (en) * 2006-12-07 2014-11-18 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved storage stability
WO2008072535A1 (ja) 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
CA2685331C (en) 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
KR101912709B1 (ko) 2009-05-13 2018-10-30 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
WO2016203018A1 (en) 2015-06-19 2016-12-22 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
CA2703697C (en) * 2000-07-06 2012-09-04 Daiichi Sankyo Company, Limited Acid addition salts of hydropyridine derivatives
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
CN100341506C (zh) * 2000-12-25 2007-10-10 三共株式会社 含有阿斯匹林的药用组合物
EP1660183A2 (en) * 2003-05-05 2006-05-31 Eli Lilly and Company Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4)

Also Published As

Publication number Publication date
NO20080244L (no) 2008-01-14
KR20080016647A (ko) 2008-02-21
BRPI0612624A2 (pt) 2016-11-29
US20090156632A1 (en) 2009-06-18
ECSP078014A (es) 2008-01-23
WO2006138317A2 (en) 2006-12-28
EP1893205A2 (en) 2008-03-05
GT200600263A (es) 2007-02-23
CN101198329A (zh) 2008-06-11
AU2006259538A1 (en) 2006-12-28
MX2007015430A (es) 2008-02-21
EP1893205A4 (en) 2010-06-30
MA29722B1 (fr) 2008-09-01
WO2006138317A3 (en) 2007-05-03
IL187486A0 (en) 2008-06-05
CA2612315A1 (en) 2006-12-28
JP2008543853A (ja) 2008-12-04
EA200800075A1 (ru) 2008-04-28
ZA200710769B (en) 2009-09-30

Similar Documents

Publication Publication Date Title
TNSN07474A1 (en) Dosage regimen for prasugrel
IL189546A0 (en) Therapy for the treatment of disease
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
NZ514464A (en) Apomorphine and sildenafil composition
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MXPA05012810A (es) Formas de dosis oral de memantina.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
SI1965797T1 (sl) Zmanjĺ anje omotice, neĺ˝elenega uäśinka, ki je povezan s terapijo s pirfenidonom
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
WO2000057867A3 (en) Improved cancer treatment with temozolomide
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
WO2007144889A3 (en) Treatment of neurofibromatosis
WO2004071398A3 (en) Pharmaceutical patch
TW200626133A (en) Oral medication for twice-daily administration
CR9572A (es) Regimen de dosificacion para prasugrel
WO2007074170A3 (en) Compositions and methods for the treatment and prevention of disease
BRPI0503488A (pt) agente de tratamento para sìndrome de intestino irritável com diarréia predominante
WO2006036956A3 (en) Therapeutic regimen for treating cancer using quassinoids and other chemotherapeutic agents
HK1133829A (en) Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer